Mind Medicine (MNMD) has released an update.
Mind Medicine (MindMed) Inc. has presented promising results from its Phase 2b study of MM120, a treatment for Generalized Anxiety Disorder (GAD), showing significant efficacy and sustained benefits over 12 weeks from a single dose. The study, showcased at the APA Annual Meeting, demonstrates the drug’s potential to become a new treatment option for GAD, a condition with limited recent advancements in medication.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
